Shattuck Labs, Inc. (STTK): Cash & Equivalents
$54.19M
As of 2025-12-31
$63.30M
As of 2026-06-30
+4.6%
3-year compound annual growth
-19.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $54.19M | -5.6% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $57.39M | -54.3% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $125.63M | +165.2% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $47.38M | -48.7% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $92.27M | -41.6% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $157.90M | n/m | 2022-03-15, Balance as of period end |
| 2019-12-31 | $7.01M | n/a | 2021-03-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $54.19M | -5.6% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.51M | -9.0% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $24.71M | +57.4% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $52.77M | n/m |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $28.18M | +55.7% |
| Rallybio Corp (RLYB) | 2025-12-31 | $31.37M | +125.7% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.66M | -75.8% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
Compare STTK, SXTP, DARE, RFL side by side · Screen every company in Pharmaceutical Preparations ↗